Denali Therapeutics Inc. Insider Trading for March 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Denali Therapeutics Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Denali Therapeutics Inc. for March 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31 2021 | DNLI | Denali Therapeutic ... | Ho Carole | Chief Medical Offic ... | Sell | S | 54.62 | 2,822 | 154,126 | 162,319 | 165.1 K to 162.3 K (-1.71 %) |
| Mar 16 2021 | DNLI | Denali Therapeutic ... | Krognes Steve E. | CFO and Treasurer | Sell | S | 63.67 | 1,158 | 73,730 | 850,000 | 851.2 K to 850 K (-0.14 %) |
| Mar 16 2021 | DNLI | Denali Therapeutic ... | Krognes Steve E. | CFO and Treasurer | Sell | S | 62.71 | 3,258 | 204,319 | 851,158 | 854.4 K to 851.2 K (-0.38 %) |
| Mar 16 2021 | DNLI | Denali Therapeutic ... | Krognes Steve E. | CFO and Treasurer | Sell | S | 62.04 | 32,326 | 2,005,602 | 854,416 | 886.7 K to 854.4 K (-3.65 %) |
| Mar 16 2021 | DNLI | Denali Therapeutic ... | Krognes Steve E. | CFO and Treasurer | Sell | S | 61.16 | 13,258 | 810,912 | 886,742 | 900 K to 886.7 K (-1.47 %) |
| Mar 04 2021 | DNLI | Denali Therapeutic ... | Schuth Alexander O. | COO and Secretary | Sell | S | 61.58 | 1,878 | 115,647 | 531,582 | 533.5 K to 531.6 K (-0.35 %) |
| Mar 04 2021 | DNLI | Denali Therapeutic ... | Schuth Alexander O. | COO and Secretary | Sell | S | 60.89 | 8,122 | 494,524 | 533,460 | 541.6 K to 533.5 K (-1.50 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Ho Carole | Chief Medical Offic ... | Sell | S | 71.27 | 68 | 4,846 | 165,141 | 165.2 K to 165.1 K (-0.04 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Ho Carole | Chief Medical Offic ... | Sell | S | 70.07 | 125 | 8,758 | 165,209 | 165.3 K to 165.2 K (-0.08 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Ho Carole | Chief Medical Offic ... | Sell | S | 68.87 | 208 | 14,324 | 165,334 | 165.5 K to 165.3 K (-0.13 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Ho Carole | Chief Medical Offic ... | Sell | S | 68.01 | 1,320 | 89,772 | 165,542 | 166.9 K to 165.5 K (-0.79 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Ho Carole | Chief Medical Offic ... | Sell | S | 67.07 | 1,173 | 78,670 | 166,862 | 168 K to 166.9 K (-0.70 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Ho Carole | Chief Medical Offic ... | Sell | S | 65.74 | 2,871 | 188,725 | 168,035 | 170.9 K to 168 K (-1.68 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Ho Carole | Chief Medical Offic ... | Sell | S | 64.54 | 1,327 | 85,646 | 170,906 | 172.2 K to 170.9 K (-0.77 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 71.35 | 1,031 | 73,563 | 2,642,296 | 2.6 M to 2.6 M (-0.04 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 69.59 | 3,482 | 242,309 | 2,643,327 | 2.6 M to 2.6 M (-0.13 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 68.50 | 6,011 | 411,778 | 2,646,809 | 2.7 M to 2.6 M (-0.23 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 67.57 | 14,945 | 1,009,834 | 2,652,820 | 2.7 M to 2.7 M (-0.56 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 66.55 | 18,316 | 1,219,003 | 2,667,765 | 2.7 M to 2.7 M (-0.68 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 65.63 | 37,445 | 2,457,665 | 2,686,081 | 2.7 M to 2.7 M (-1.37 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 64.36 | 18,770 | 1,208,056 | 2,723,526 | 2.7 M to 2.7 M (-0.68 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Watts Ryan J. | President and CEO | Sell | S | 70.92 | 68 | 4,823 | 2,305,742 | 2.3 M to 2.3 M (0.00 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Watts Ryan J. | President and CEO | Sell | S | 69.65 | 594 | 41,371 | 2,305,810 | 2.3 M to 2.3 M (-0.03 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Watts Ryan J. | President and CEO | Sell | S | 68.46 | 1,625 | 111,246 | 2,306,404 | 2.3 M to 2.3 M (-0.07 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Watts Ryan J. | President and CEO | Sell | S | 67.69 | 3,339 | 226,017 | 2,308,029 | 2.3 M to 2.3 M (-0.14 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Watts Ryan J. | President and CEO | Sell | S | 66.55 | 3,453 | 229,780 | 2,311,368 | 2.3 M to 2.3 M (-0.15 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Watts Ryan J. | President and CEO | Sell | S | 65.63 | 5,885 | 386,209 | 2,314,821 | 2.3 M to 2.3 M (-0.25 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Watts Ryan J. | President and CEO | Sell | S | 64.42 | 3,370 | 217,106 | 2,320,706 | 2.3 M to 2.3 M (-0.15 %) |